Stockscreener 앱 받기
0.958
2.02%
0.019
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
CRDF S-8 & SEC Filings - Yahoo Finance Australia
CRDF 8-K & SEC Filings - Yahoo Finance Australia
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance Singapore
Is Cardiff Oncology (NASDAQ:CRDF) Building a More Durable Market Story? - Kalkine Media
Verastem, Inc. (VSTM) stock price, news, quote and history - au.finance.yahoo.com
Cardiff Oncology (Nasdaq:CRDF)Stock Analysis - Simply Wall Street
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com Canada
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com UK
Cardiff Oncology settles dispute with NMS over onvansertib rights By Investing.com - Investing.com UK
Form 8K Cardiff Oncology Inc For: 14 September By Investing.com - Investing.com India
Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development SummitSlideshow - Seeking Alpha
Cardiff Oncology (CRDF) Slips to $1.02 as Biotech Stock Holds Above Key SupportNarrow Range Breakout - dars.gov.et
Cardiff Oncology Announces Upcoming Conference Participation for Mani Mohindru, Ph.D. - Quiver Quantitative
Cardiff Oncology to Participate in September 2026 Conferences - GlobeNewswire
Cardiff Oncology will take part in two September cancer conferences - Stock Titan
Cardiff Oncology Inc. (CRDF) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Cardiff Oncology Inc. (CRDF) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cardiff Oncology (NASDAQ: CRDF) seeks share boost that may dilute holders - Stock Titan
Equities Analysts Offer Predictions for CRDF Q3 Earnings - MarketBeat
Enterprise value to EBIT forward of Cardiff Oncology, Inc. – DUS:XE7C - tradingview.com
symbol__ Stock Quote Price and Forecast - CNN
Cardiff Oncology (CRDF) asks investors to double authorized common shares - Stock Titan
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsFibonacci Extension - vinanet.vn
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsOverbought Signal Alerts - careplusvn.com
Cardiff Oncology (CRDF) Holds Near $0.98 as Consolidation PersistsVolume Weighted Price - dars.gov.et
CRDF PRE 14A & SEC Filings - Yahoo Finance Australia
CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - webull.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
William Blair downgrades Cardiff Oncology (CRDF) to a Hold - The Globe and Mail
CRDF Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform - marketscreener.com
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $6 - Moomoo
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty - Investing.com
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com Canada
William Blair downgrades Cardiff Oncology stock rating on rights uncertainty By Investing.com - Investing.com UK
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Is Cardiff Oncology Inc (CRDF) Moving in the Right Direction Aft - GuruFocus
Cardiff Oncology: Q2 Earnings Snapshot - AOL.com
Cardiff Oncology: Q2 Earnings Snapshot - KTVB
Cardiff Oncology Q2 operating expenses fall on lower R&D costs - TradingView
Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - GlobeNewswire
Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - finance.yahoo.com
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update - stocktitan.net
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
0.01%
0.71%
자본화:
|
볼륨(24시간):